Liminatus Pharma logo

Liminatus Pharma(NASDAQ) LIMNW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-61%
5 YearN/A
1 Year-71%
1 Month-1%
$0.04
-12.48%
-0.01Today
Liminatus Pharma last closing stock price
MetricPriceDate
Last closeUSD 0.042026-10-12
Liminatus Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.71%USD 0.062026-09-30
1 month-0.57%USD 0.042026-09-10
3 month-13.27%USD 0.052026-07-14
Year to date+24.15%USD 0.042025-12-31
1 year-70.54%USD 0.152025-10-10
Since inception-60.53%USD 0.112025-05-01

Liminatus Pharma Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$12.52M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$0.04

Volume

100

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.03 - $0.19

Estimated Earnings Date

N/A

LIMNW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Liminatus Pharma

Liminatus Pharma, Inc. is an immuno-oncology firm based in La Palma, California, focused on developing innovative cancer treatments. The company is actively engaged in clinical trials to advance its therapeutic offerings in the biotechnology sector.

Products and Services
  • Innovative immuno-oncology therapies for various cancers
  • Clinical trial management and research services
  • Collaboration with healthcare institutions for drug development
Growth Outlook
  • Strong focus on expanding clinical trial portfolio to enhance treatment options
  • Potential partnerships with leading healthcare organizations for research
  • Increasing demand for advanced cancer therapies in the healthcare market
Financial Highlights
  • Recent quarterly net income of -$1,407,259, reflecting ongoing investment in R&D
  • Cash and cash equivalents of $3,017,096 as of June 30, 2026
  • Trailing twelve months (TTM) cash flow from operations shows significant investment in growth
Liminatus Pharma, Inc. is positioned in a rapidly evolving biotechnology landscape, with a commitment to developing cutting-edge cancer therapies. The company's focus on clinical trials and partnerships may provide opportunities for growth and innovation in the healthcare sector. Recent financial data indicates a strong cash position, which could support ongoing research and development efforts. As the demand for effective cancer treatments continues to rise, Liminatus Pharma's strategic initiatives may enhance its market presence and potential for future success.
AI Generated • Sep 18, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Cerritos, CA 90703, US

LIMNW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

443.60%

Return on Capital

N/A

Return on Assets

-367.93%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

0

Volume

100

Avg. Volume

1.48K

Financials (TTM)

Gross Profit

-$986.00

Operating Income

-$4.07M

EBITDA

-$12.44M

Operating Cash Flow

-$3.97M

Capital Expenditure

-$13.11K

Free Cash Flow

-$3.99M

Cash & ST Invst.

$3.02M

Total Debt

$1.44M

Liminatus Pharma Performance Analysis

Liminatus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Liminatus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-1477.6%
Q42025-12-31-344.4%
Q12026-03-3184.2%
Q22026-06-30-25.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$468.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

1

N/A

Net Income

-$1.41M

-1342.2%

EBITDA

-$1.38M

-881.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.02M

+125.5%

Total Debt

$1.44M

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$1.44M

+0.0%

Return on Assets

-3.68%

N/A

Return on Invested Capital

-11.19%

N/A

Free Cash Flow

-$970.00K

+89.2%

Operating Cash Flow

-$970.00K

+89.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XRTXXORTX Therapeutics Inc.
$1.58-5.95%
GLMDGalmed Pharmaceuticals Ltd.
$4.63+21.05%
PTIXProtagenic Therapeutics, Inc.
$0.80-0.74%
CEROCERo Therapeutics Holdings, Inc.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
INTCIntel
$98.12-4.56%

Questions About LIMNW

What is the current price of Liminatus Pharma?

Liminatus Pharma is trading at $0.04 per share.

What is the 52-week range for Liminatus Pharma?

Over the past 52 weeks, Liminatus Pharma has traded between $0.03 and $0.19.

How much debt does Liminatus Pharma have?

Liminatus Pharma total debt is unavailable.

How much cash does Liminatus Pharma have on hand?

Liminatus Pharma does not have cash on hand data available.

What is Liminatus Pharma’s dividend yield?

Liminatus Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services